quinolinic acid has been researched along with Dementia Praecox in 25 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The tryptophan catabolite (TRYCAT) pathway is implicated in the pathophysiology of schizophrenia (SCZ) since the rate-limiting enzyme indoleamine-dioxygenase (IDO) may be induced by inflammatory and oxidative stress mediators." | 9.22 | The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. ( Al-Hakeim, HK; Almulla, AF; Maes, M; Solmi, M; Tunvirachaisakul, C; Vasupanrajit, A; Verkerk, R, 2022) |
| "The kynurenine (KYN) pathway is postulated to play various roles in immune system dysregulation of schizophrenia (SCZ)." | 9.12 | Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis. ( Cao, B; Chen, Y; McIntyre, RS; Pan, Z; Ren, Z; Wang, D, 2021) |
| "The kynurenine pathway (KP) has been proposed as indirect link between systemic immune responses and clinical symptom development in schizophrenia spectrum disorders (SSD)." | 9.05 | Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis. ( Coppens, V; De Picker, L; Kampen, JK; Morrens, M, 2020) |
| "A number of tryptophan metabolites known to be neuroactive have been examined for their potential associations with cognitive deficits in schizophrenia." | 8.02 | Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia. ( Chiappelli, J; Cui, Y; Hong, LE; Huang, J; Kochunov, P; Tan, S; Tan, Y; Tian, B; Tian, L; Tong, J; Wang, Z; Yang, F; Zhang, P; Zhou, Y, 2021) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 8.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 7.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential." | 7.88 | Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "The concentration of the endogenous excitotoxin quinolinic acid was determined in the cerebrospinal fluid of drug-free patients suffering from Huntington's disease or schizophrenia (control group)." | 7.67 | Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. ( Kurlan, R; Schwarcz, R; Shoulson, I; Tamminga, CA, 1988) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 5.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "The tryptophan catabolite (TRYCAT) pathway is implicated in the pathophysiology of schizophrenia (SCZ) since the rate-limiting enzyme indoleamine-dioxygenase (IDO) may be induced by inflammatory and oxidative stress mediators." | 5.22 | The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. ( Al-Hakeim, HK; Almulla, AF; Maes, M; Solmi, M; Tunvirachaisakul, C; Vasupanrajit, A; Verkerk, R, 2022) |
| "The kynurenine (KYN) pathway is postulated to play various roles in immune system dysregulation of schizophrenia (SCZ)." | 5.12 | Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis. ( Cao, B; Chen, Y; McIntyre, RS; Pan, Z; Ren, Z; Wang, D, 2021) |
| "The kynurenine pathway (KP) has been proposed as indirect link between systemic immune responses and clinical symptom development in schizophrenia spectrum disorders (SSD)." | 5.05 | Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis. ( Coppens, V; De Picker, L; Kampen, JK; Morrens, M, 2020) |
| "A number of tryptophan metabolites known to be neuroactive have been examined for their potential associations with cognitive deficits in schizophrenia." | 4.02 | Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia. ( Chiappelli, J; Cui, Y; Hong, LE; Huang, J; Kochunov, P; Tan, S; Tan, Y; Tian, B; Tian, L; Tong, J; Wang, Z; Yang, F; Zhang, P; Zhou, Y, 2021) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 4.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 3.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential." | 3.88 | Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Increased cytokines and kynurenic acid (KYNA) levels in cerebrospinal fluid (CSF) have been reported in patients with schizophrenia and bipolar disorder." | 3.85 | Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity. ( Bhat, M; Cannon, TD; Engberg, G; Erhardt, S; Hultman, CM; Johansson, V; Kegel, ME; Landén, M; Schuppe-Koistinen, I; Schwieler, L; Wetterberg, L, 2017) |
| "The concentration of the endogenous excitotoxin quinolinic acid was determined in the cerebrospinal fluid of drug-free patients suffering from Huntington's disease or schizophrenia (control group)." | 3.67 | Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. ( Kurlan, R; Schwarcz, R; Shoulson, I; Tamminga, CA, 1988) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 1.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "Thus, nociceptive and neuropathic pain belongs--in addition to behavioral changes--among the parameters which are affected in described animal models of schizophrenia." | 1.36 | Pain perception in neurodevelopmental animal models of schizophrenia. ( Bubeníková-Valešová, V; Franěk, M; Rokyta, R; Šťastný, F; Vaculín, S; Yamamotová, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almulla, AF | 1 |
| Vasupanrajit, A | 1 |
| Tunvirachaisakul, C | 1 |
| Al-Hakeim, HK | 1 |
| Solmi, M | 1 |
| Verkerk, R | 1 |
| Maes, M | 4 |
| Morrens, M | 1 |
| De Picker, L | 1 |
| Kampen, JK | 1 |
| Coppens, V | 1 |
| Cao, B | 1 |
| Chen, Y | 1 |
| Ren, Z | 1 |
| Pan, Z | 1 |
| McIntyre, RS | 1 |
| Wang, D | 1 |
| Huang, J | 1 |
| Tong, J | 1 |
| Zhang, P | 1 |
| Zhou, Y | 1 |
| Cui, Y | 1 |
| Tan, S | 1 |
| Wang, Z | 1 |
| Yang, F | 1 |
| Kochunov, P | 1 |
| Chiappelli, J | 1 |
| Tian, B | 1 |
| Tian, L | 1 |
| Tan, Y | 1 |
| Hong, LE | 1 |
| Cathomas, F | 1 |
| Guetter, K | 1 |
| Seifritz, E | 1 |
| Klaus, F | 1 |
| Kaiser, S | 1 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Kanchanatawan, B | 3 |
| Beggiato, S | 1 |
| Notarangelo, FM | 1 |
| Sathyasaikumar, KV | 1 |
| Giorgini, F | 1 |
| Schwarcz, R | 2 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Fazio, F | 1 |
| Corigliano, V | 1 |
| Comparelli, A | 1 |
| Ferracuti, S | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Baldessarini, RJ | 1 |
| Johansson, V | 2 |
| Erhardt, S | 2 |
| Engberg, G | 2 |
| Kegel, M | 1 |
| Bhat, M | 2 |
| Schwieler, L | 2 |
| Blennow, K | 1 |
| Zetterberg, H | 1 |
| Cannon, TD | 2 |
| Wetterberg, L | 2 |
| Hultman, CM | 2 |
| Landén, M | 2 |
| Zavitsanou, K | 1 |
| Lim, CK | 1 |
| Purves-Tyson, T | 1 |
| Karl, T | 1 |
| Kassiou, M | 1 |
| Banister, SD | 1 |
| Guillemin, GJ | 1 |
| Weickert, CS | 1 |
| Gos, T | 1 |
| Myint, AM | 1 |
| Schiltz, K | 1 |
| Meyer-Lotz, G | 1 |
| Dobrowolny, H | 1 |
| Busse, S | 1 |
| Müller, UJ | 1 |
| Mawrin, C | 1 |
| Bernstein, HG | 1 |
| Bogerts, B | 1 |
| Steiner, J | 1 |
| Kegel, ME | 1 |
| Schuppe-Koistinen, I | 1 |
| Sirivichayakul, S | 2 |
| Ruxrungtham, K | 2 |
| Carvalho, AF | 2 |
| Geffard, M | 2 |
| Ormstad, H | 1 |
| Anderson, G | 2 |
| Franěk, M | 1 |
| Vaculín, S | 1 |
| Yamamotová, A | 1 |
| Šťastný, F | 1 |
| Bubeníková-Valešová, V | 1 |
| Rokyta, R | 1 |
| Möller, M | 1 |
| Du Preez, JL | 1 |
| Harvey, BH | 1 |
| St'astný, F | 1 |
| Tejkalová, H | 1 |
| Bubeníková, V | 1 |
| Klaschka, J | 1 |
| Formánek, J | 1 |
| Frantík, E | 1 |
| Uehara, T | 2 |
| Sumiyoshi, T | 2 |
| Matsuoka, T | 1 |
| Itoh, H | 1 |
| Kurachi, M | 2 |
| DeLisi, LE | 1 |
| Tanii, Y | 1 |
| Ravikumar, A | 1 |
| Deepadevi, KV | 1 |
| Arun, P | 1 |
| Manojkumar, V | 1 |
| Kurup, PA | 1 |
| Stone, TW | 1 |
| Markey, SP | 1 |
| Boni, RL | 1 |
| Yergey, JA | 1 |
| Heyes, MP | 1 |
| Tamminga, CA | 1 |
| Kurlan, R | 1 |
| Shoulson, I | 1 |
6 reviews available for quinolinic acid and Dementia Praecox
| Article | Year |
|---|---|
The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenic Acid; Kynurenine; Quinolinic Acid; Schizophr | 2022 |
Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis.
Topics: Aged; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid; Schizophrenia; Tryptophan | 2020 |
Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis.
Topics: Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid; Schizophrenia; Tryptophan | 2021 |
Is there a viral or immune dysfunction etiology to schizophrenia? Re-evaluation a decade later.
Topics: Antibodies, Viral; Diarrhea Viruses, Bovine Viral; Female; Humans; Influenza, Human; Interleukin-2; | 1996 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
Mass spectrometric determinations of tryptophan and its metabolites.
Topics: Animals; Body Fluids; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Melatonin; Mo | 1991 |
19 other studies available for quinolinic acid and Dementia Praecox
| Article | Year |
|---|---|
Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia.
Topics: Humans; Kynurenic Acid; Kynurenine; Memory, Short-Term; Quinolinic Acid; Schizophrenia; Tryptophan | 2021 |
Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.
Topics: Adult; Case-Control Studies; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Female; H | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Cognition Disorders; Executive Function; Female; Huma | 2018 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid.
Topics: Adult; Aged; Bipolar Disorder; Chemokine CCL2; Cohort Studies; Female; Humans; Kynurenic Acid; Male; | 2020 |
Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition.
Topics: Animals; Brain; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dizocilpine Maleate; | 2014 |
Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients.
Topics: Adult; CA1 Region, Hippocampal; Cell Count; Excitatory Amino Acid Agonists; Female; Glutamic Acid; H | 2014 |
Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity.
Topics: Bipolar Disorder; Female; Humans; Interleukin-6; Interleukin-8; Kynurenic Acid; Male; Middle Aged; P | 2017 |
Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Immunoglobulin A; Inflammation; Male; Middle Aged; P | 2018 |
Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.
Topics: Adult; Biomarkers; Female; Humans; Immunity, Cellular; Immunoglobulin M; Kynurenic Acid; Male; Metab | 2018 |
Pain perception in neurodevelopmental animal models of schizophrenia.
Topics: Age Factors; Animals; Animals, Newborn; Dipeptides; Disease Models, Animal; Female; Hot Temperature; | 2010 |
Development and validation of a single analytical method for the determination of tryptophan, and its kynurenine metabolites in rat plasma.
Topics: 3-Hydroxyanthranilic Acid; Animals; Charcoal; Chromatography, High Pressure Liquid; Depression; Kynu | 2012 |
[Glutamate receptor dysfunction and psychosis-like behavior in an animal model].
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Disease Models, Animal; Quinolinic Acid; Rats; R | 2003 |
Effect of prefrontal cortex inactivation on behavioral and neurochemical abnormalities in rats with excitotoxic lesions of the entorhinal cortex.
Topics: Amygdala; Anesthetics, Local; Animals; Denervation; Disease Models, Animal; Dopamine; Dopamine Uptak | 2007 |
Neonatal lesions of the left entorhinal cortex affect dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Animals, Newborn; Brain; Caudate Nucleus; Disease | 2000 |
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythro | 2000 |
Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia.
Topics: Adolescent; Adult; Female; Humans; Huntington Disease; Male; Middle Aged; Pyridines; Quinolinic Acid | 1988 |